Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18651603,flow rate,"Chromatographic separation was carried on an Acquity UPLC BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with an isocratic mobile phase consisting of acetonitrile and containing 0.1% formic acid (75:25, v/v) at flow rate of 0.4 mL/min, and total run time was within 1 min.","Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651603/),[ml] / [min],0.4,28,DB00203,Sildenafil
,18651603,total run time,"Chromatographic separation was carried on an Acquity UPLC BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with an isocratic mobile phase consisting of acetonitrile and containing 0.1% formic acid (75:25, v/v) at flow rate of 0.4 mL/min, and total run time was within 1 min.","Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651603/),min,1,29,DB00203,Sildenafil
,25899974,flow rate,"The mobile phase, 0.02M ammonium acetate buffer:acetonitrile (48:52, v/v), was run at a flow rate of 1.0mL/min, and the column eluent was monitored using an ultraviolet detector at 254nm at room temperature.",Validated high-performance liquid chromatography method for the determination of a phosphodiesterase inhibitor SK5474 in rat plasma and its application to pharmacokinetic study of SK5474. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25899974/),[ml] / [min],1.0,14210,DB00203,Sildenafil
,25899974,retention times,"The retention times of sildenafil and SK5474 were approximately 5.8 and 7.2min, respectively.",Validated high-performance liquid chromatography method for the determination of a phosphodiesterase inhibitor SK5474 in rat plasma and its application to pharmacokinetic study of SK5474. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25899974/),min,5.8,14211,DB00203,Sildenafil
,25899974,retention times,"The retention times of sildenafil and SK5474 were approximately 5.8 and 7.2min, respectively.",Validated high-performance liquid chromatography method for the determination of a phosphodiesterase inhibitor SK5474 in rat plasma and its application to pharmacokinetic study of SK5474. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25899974/),min,7.2,14212,DB00203,Sildenafil
,25899974,F (fraction absorbed),"After p.o. administration (30mg/kg) of SK5474, F (fraction absorbed) value was approximately 46.0%.",Validated high-performance liquid chromatography method for the determination of a phosphodiesterase inhibitor SK5474 in rat plasma and its application to pharmacokinetic study of SK5474. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25899974/),%,46.0,14213,DB00203,Sildenafil
,26804967,maximum concentration (Cmax ),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],8.06,15432,DB00203,Sildenafil
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],7.69,15433,DB00203,Sildenafil
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],5.66,15434,DB00203,Sildenafil
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],5.12,15435,DB00203,Sildenafil
,26804967,Cmax,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],173,15436,DB00203,Sildenafil
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],476,15437,DB00203,Sildenafil
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],",",15438,DB00203,Sildenafil
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],268,15439,DB00203,Sildenafil
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],577,15440,DB00203,Sildenafil
,33185345,maximum concentration,"An earlier achievement of the maximum concentration of sildenafil was detected when taking the test drug compared with the standard form (51 and 62 minutes, respectively, Z-value=-2.25, p-value=0.0244).",[Pharmacokinetic features of sildenafil spray in healthy men depending on food intake]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33185345/),min,51,16805,DB00203,Sildenafil
,33185345,maximum concentration,"An earlier achievement of the maximum concentration of sildenafil was detected when taking the test drug compared with the standard form (51 and 62 minutes, respectively, Z-value=-2.25, p-value=0.0244).",[Pharmacokinetic features of sildenafil spray in healthy men depending on food intake]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33185345/),min,62,16806,DB00203,Sildenafil
above,22329523,Cmax,"Our patients both experienced sildenafil Cmax above 500 ng/mL; however, they did not report any significant adverse reactions to sildenafil during the follow-up period.",Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329523/),[ng] / [ml],500,22198,DB00203,Sildenafil
,26139313,biological half-life,"The serum concentration further declined to 9.2 and 2.3 µg/mL, respectively, 5 and 14 h later, revealing a biological half-life of 4.2 h.",A Non-Fatal Self-Poisoning Attempt with Sildenafil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26139313/),h,4.2,29211,DB00203,Sildenafil
,11879254,absolute oral bioavailability,The calculated absolute oral bioavailability of sildenafil was 41% (90% CI: 36--47).,"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879254/),%,41,30241,DB00203,Sildenafil
,11879254,absolute bioavailability,Sildenafil had a mean absolute bioavailability of 41%.,"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879254/),%,41,30242,DB00203,Sildenafil
,11823754,oral bioavailability,"Because of extensive first-pass metabolism, oral bioavailability of sildenafil reaches only 40%.",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),%,40,30295,DB00203,Sildenafil
,11823754,area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity),"Grapefruit juice changed the area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity) from 620 [1.53] ng/ml x h to 761 [1.58] ng/ml x h (geometric mean with geometric standard deviation), corresponding to a 23% increase (90% confidence interval, 13%-33%).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),[ng] / [h·ml],620,30296,DB00203,Sildenafil
,11823754,area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity),"Grapefruit juice changed the area under the sildenafil plasma concentration-time curve from time zero to infinity [AUC(0-infinity) from 620 [1.53] ng/ml x h to 761 [1.58] ng/ml x h (geometric mean with geometric standard deviation), corresponding to a 23% increase (90% confidence interval, 13%-33%).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),[ng] / [h·ml],761,30297,DB00203,Sildenafil
,11823754,time to reach C(max),"There was a trend toward a prolonged time to reach C(max) during the grapefruit juice period (from a median of 0.75 hour to a median of 1.13 hours), corresponding to an increase by 0.25 hour (90% confidence interval, 0-0.63 hour).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),h,0.75,30298,DB00203,Sildenafil
,11823754,time to reach C(max),"There was a trend toward a prolonged time to reach C(max) during the grapefruit juice period (from a median of 0.75 hour to a median of 1.13 hours), corresponding to an increase by 0.25 hour (90% confidence interval, 0-0.63 hour).",Effects of grapefruit juice on the pharmacokinetics of sildenafil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11823754/),h,1.13,30299,DB00203,Sildenafil
,31141964,oral bioavailability,"The method was applied to examine the pharmacokinetics of desoxo-narchinol A, and the oral bioavailability of desoxo-narchinol A was 18.1% in rats and 28.4% in mice.",Liquid Chromatography-Tandem Mass Spectrometry of Desoxo-Narchinol a and Its Pharmacokinetics and Oral Bioavailability in Rats and Mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31141964/),%,18.1,31372,DB00203,Sildenafil
,31141964,oral bioavailability,"The method was applied to examine the pharmacokinetics of desoxo-narchinol A, and the oral bioavailability of desoxo-narchinol A was 18.1% in rats and 28.4% in mice.",Liquid Chromatography-Tandem Mass Spectrometry of Desoxo-Narchinol a and Its Pharmacokinetics and Oral Bioavailability in Rats and Mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31141964/),%,28.4,31373,DB00203,Sildenafil
,29869515,EE%,"SIL-loaded cubosomes showed EE% ranging between 32.15 and 72.01%, particle size in the range of 150.81-446.02 nm and sustained drug release over 8 h.",Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869515/),%,32.15 and 72.01,35785,DB00203,Sildenafil
,21881249,flow rate,"Chromatographic separation was performed using Pursuit XRS C₁₈ column (50 mm × 2.1 mm, i.d., 3 μm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min.",Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21881249/),[ml] / [min],0.2,37191,DB00203,Sildenafil
,21881249,total run time,"Chromatographic separation was performed using Pursuit XRS C₁₈ column (50 mm × 2.1 mm, i.d., 3 μm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min.",Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21881249/),min,2.5,37192,DB00203,Sildenafil
over,31740991,target plasma concentration,We developed a pharmacokinetic model of intravenous sildenafil in newborns with congenital diaphragmatic hernia (CDH) to achieve a target plasma concentration of over 50 μg/l.,Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31740991/),[μg] / [l],50,39502,DB00203,Sildenafil
,18760744,time interval,"The median [CI: 95%] of the time interval between drug intake and sexual intercourses was 1.0h [1.0-1.0] for sildenafil, 1.0h [1.0-1.0] for vardenafil and 1.5h [1.3-1.5] for tadalafil.",[Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760744/),h,1.0,39541,DB00203,Sildenafil
,18760744,time interval,"The median [CI: 95%] of the time interval between drug intake and sexual intercourses was 1.0h [1.0-1.0] for sildenafil, 1.0h [1.0-1.0] for vardenafil and 1.5h [1.3-1.5] for tadalafil.",[Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18760744/),h,1.5,39542,DB00203,Sildenafil
,32095467,Cmax,"For UI14SDF100CW, the Cmax and AUClast of sildenafil were 1068.69 ± 458.25 (mean ± standard deviation) mg/L and 3580.59 ± 1680.29 h·mg/L, and the corresponding values for Viagra® were 1146.84 ± 501.70 mg/L and 3406.35 ± 1452.31 h·/L, respectively.",Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095467/),[mg] / [l],1068.69,42443,DB00203,Sildenafil
,32095467,Cmax,"For UI14SDF100CW, the Cmax and AUClast of sildenafil were 1068.69 ± 458.25 (mean ± standard deviation) mg/L and 3580.59 ± 1680.29 h·mg/L, and the corresponding values for Viagra® were 1146.84 ± 501.70 mg/L and 3406.35 ± 1452.31 h·/L, respectively.",Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095467/),[mg] / [l],1146.84,42444,DB00203,Sildenafil
,32095467,AUClast,"For UI14SDF100CW, the Cmax and AUClast of sildenafil were 1068.69 ± 458.25 (mean ± standard deviation) mg/L and 3580.59 ± 1680.29 h·mg/L, and the corresponding values for Viagra® were 1146.84 ± 501.70 mg/L and 3406.35 ± 1452.31 h·/L, respectively.",Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095467/),[h·mg] / [l],3580.59,42445,DB00203,Sildenafil
,32095467,AUClast,"For UI14SDF100CW, the Cmax and AUClast of sildenafil were 1068.69 ± 458.25 (mean ± standard deviation) mg/L and 3580.59 ± 1680.29 h·mg/L, and the corresponding values for Viagra® were 1146.84 ± 501.70 mg/L and 3406.35 ± 1452.31 h·/L, respectively.",Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095467/),[h] / [l],3406.35,42446,DB00203,Sildenafil
,28025967,tmax,"When sildenafil was given with high-fat meals, mean C<sub>max</sub> was reduced by 23%, and median tmax ranged from 0.75 to 1.50 hours (p ≤ 0.05).","A single dose, randomized, open-label, cross-over bioequivalence study of sildenafil citrate tablets in healthy Chinese volunteers . ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025967/),h,0.75 to 1.50,48606,DB00203,Sildenafil
,27809343,flow rate,"The mobile phase, 0.02 m ammonium acetate buffer:acetonitrile (48:52, v/v), was run at a flow rate of 1.0 mL/min at room temperature, and the column eluent was monitored using an ultraviolet detector at 280 nm.","Validated high-performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27809343/),[ml] / [min],1.0,62826,DB00203,Sildenafil
,27809343,retention times,"The retention times of JW-55 and sildenafil were ~5.9 and 7.7 min, respectively.","Validated high-performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27809343/),min,5.9,62827,DB00203,Sildenafil
,27809343,retention times,"The retention times of JW-55 and sildenafil were ~5.9 and 7.7 min, respectively.","Validated high-performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27809343/),min,7.7,62828,DB00203,Sildenafil
,27809343,detection limit,The detection limit of JW-55 in rat plasma was 0.03 μg/mL.,"Validated high-performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27809343/),[μg] / [ml],0.03,62829,DB00203,Sildenafil
,27809343,F,"After oral administration, the F value was approximately 73.7%.","Validated high-performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide in rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27809343/),%,73.7,62830,DB00203,Sildenafil
,32095455,flow rate,"Chromatographic separation was performed on a Shiseido C18 (100 × 2.1 mm, 2.7 µm) column with isocratic elution using 2.0 mM ammonium acetate and acetonitrile (55:45, v/v) with 0.1% formic acid at a flow rate of 0.7 mL/min.",Validated UPLC-MS/MS method for the determination of tadalafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095455/),[ml] / [min],0.7,63490,DB00203,Sildenafil
,32095455,total run time,The total run time was 1 min per sample.,Validated UPLC-MS/MS method for the determination of tadalafil in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32095455/),[min] / [sample],1,63491,DB00203,Sildenafil
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,87,64975,DB00203,Sildenafil
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,27,64976,DB00203,Sildenafil
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,62,64977,DB00203,Sildenafil
,19949232,clearance at 100% bioavailability,Interpatient and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS).,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),%,26,64978,DB00203,Sildenafil
,19949232,area under the curve over 24 h (AUC(24,The exposure expressed as average plasma concentration area under the curve over 24 h (AUC(24 (SIL+DMS))) ranged from 625 to 13 579 ng/h/ml.,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),[ng] / [h·ml],625 to 13 579,64979,DB00203,Sildenafil
,19949232,AUC(24,An oral dose of 4.2 mg/kg/24 h would lead to a median AUC(24 (SIL+DMS)) of 2650 ng/h/ml equivalent to 20 mg three times a day in adults.,Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),[ng] / [h·ml],2650,64980,DB00203,Sildenafil
,19949232,AUC(24,"Interpatient variability was large, with a simulated AUC(24 (SIL+DMS)) range (10th and 90th percentiles) of 1000-8000 ng/h/ml.",Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19949232/),[ng] / [h·ml],1000-8000,64981,DB00203,Sildenafil
,27392173,flow rate,"With an octadeuterated sildenafil as the internal standard, the drugs were separated via gradient elution using a C18 column and formic acid in methanol or in water as the mobile phase with a flow rate of 0.25mL/min.",A highly sensitive LC-MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27392173/),[ml] / [min],0.25,66162,DB00203,Sildenafil
,30825803,flow rate,"In this study, a reversed-phase chromatography was performed at room temperature on a C18 column with a mobile phase composed of 10 mM Na2HPO4 solution (pH 7.5): acetonitrile (45:55, v/v) at a flow rate of 0.8 mL min-1 using caffeine (CAF) as an internal standard.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[ml] / [min],0.8,66387,DB00203,Sildenafil
,30825803,total analysis time,The total analysis time was 6 min.,Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),min,6,66388,DB00203,Sildenafil
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.05,66389,DB00203,Sildenafil
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.02,66390,DB00203,Sildenafil
,21913329,LODs,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),[ng] / [ml],1.50,67607,DB00203,Sildenafil
,21913329,LODs,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),[ng] / [ml],5.00,67608,DB00203,Sildenafil
,21913329,LOQ,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),ng,5.00,67609,DB00203,Sildenafil
,21913329,LOQ,"The LODs were 1.50 and 5.00 ng/mL for SDL and DSDL, respectively, whereas the respective LOQs were 5.00 and 15.0 ng/mL.",Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),ng,15.0,67610,DB00203,Sildenafil
,21913329,Absolute recovery,Absolute recovery values for both analytes ranged from 83.1 to 93.2%.,Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21913329/),%,83.1 to 93.2,67611,DB00203,Sildenafil
,32785428,absolute bioavailability,"Since oral administration of sildenafil shows pharmacokinetic problems with mean absolute bioavailability of 41%, the goal of this work was to develop a novel sildenafil self-emulsifying drug delivery system (SEDDS) for oral absorption improvement and management of dosage.",In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32785428/),%,41,71815,DB00203,Sildenafil
,32785428,LD50,"The safety of 2-pyrrolidone/isobutanol in oral formulations was assessed in mice and no lethality was achieved in the placebo groups with LD50 of 490 mg/Kg for SEDDS II-3.3, suggesting it as a safe excipient for humans.",In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32785428/),[mg] / [kg],490,71816,DB00203,Sildenafil
,11879255,Absorption,"Absorption of sildenafil after oral administration was rapid and approximately 92% whilst the absolute bioavailability was limited to 38%, due to first-pass metabolism.",Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879255/),%,92,73008,DB00203,Sildenafil
,11879255,absolute bioavailability,"Absorption of sildenafil after oral administration was rapid and approximately 92% whilst the absolute bioavailability was limited to 38%, due to first-pass metabolism.",Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879255/),%,38,73009,DB00203,Sildenafil
,26756977,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[h·ng] / [ml],165.8,74000,DB00203,Sildenafil
,26756977,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[h·ng] / [ml],396.8,74001,DB00203,Sildenafil
,26756977,oral clearance,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[l] / [h·kg],120.6,74002,DB00203,Sildenafil
,26756977,oral clearance,"The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng•h/mL vs. 396.8 ng•h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018).",Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756977/),[l] / [h·kg],50.4,74003,DB00203,Sildenafil
,26583764,conversion factors,"Due to poor distribution into erythrocytes, drug concentrations in DBS were always lower than in plasma, resulting in conversion factors of 1.58 for ambrisentan and sildenafil and 1.52 for bosentan and tadalafil.","Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26583764/),,1.58,77354,DB00203,Sildenafil
,26583764,conversion factors,"Due to poor distribution into erythrocytes, drug concentrations in DBS were always lower than in plasma, resulting in conversion factors of 1.58 for ambrisentan and sildenafil and 1.52 for bosentan and tadalafil.","Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26583764/),,1.52,77355,DB00203,Sildenafil
,16372380,oral bioavailability,"Its oral bioavailability is only 40% due to extensive presystemic elimination, mainly by CYP3A4.",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),%,40,79257,DB00203,Sildenafil
,16372380,AUC,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],1407,79258,DB00203,Sildenafil
,16372380,AUC,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],2986,79259,DB00203,Sildenafil
,16372380,Cmax,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],287,79260,DB00203,Sildenafil
,16372380,Cmax,The pharmacokinetic analysis showed that ciprofloxacin coadministration with sildenafil significantly increased the AUC from 1407 +/- 380 to 2986 +/- 917 microg h/l (90% confidence interval 119%-159%) and the Cmax from 287 +/- 67 to 623 +/- 192 microg/l (90% confidence interval 127%-152%).,The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],623,79261,DB00203,Sildenafil
,16372380,AUC,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],1407,79262,DB00203,Sildenafil
,16372380,AUC,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[h·μg] / [l],3209,79263,DB00203,Sildenafil
,16372380,Cmax,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],287,79264,DB00203,Sildenafil
,16372380,Cmax,"Similarly, clarithromycin coadministration increased sildenafil AUC from 1407 +/- 380 to 3209 +/- 762 microg h/l (90% confidence interval 127%-161%) and Cmax from 287 +/- 67 to 694 +/- 259 microg/l (90% confidence interval 132%-157%).",The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372380/),[μg] / [l],694,79265,DB00203,Sildenafil
,24309556,flow rate,The four drugs were separated by high-performance liquid chromatography using a C18 column and an isocratic mobile phase running at a flow rate of 0.2mL/min for 5min.,"Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24309556/),[ml] / [min],0.2,88314,DB00203,Sildenafil
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.2,96896,DB00203,Sildenafil
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,2.0,96897,DB00203,Sildenafil
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.6,96898,DB00203,Sildenafil
,22232759,areas under the concentration versus time curve changes (AUCR,"The simulated versus observed areas under the concentration versus time curve changes (AUCR, severe RI/normal) were comparable for sildenafil (2.2 vs 2.0) and telithromycin (1.6 vs 1.9).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.9,96899,DB00203,Sildenafil
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,1.2,96900,DB00203,Sildenafil
,22232759,AUCR,"For repaglinide, the initial, simulated AUCR was lower than that observed (1.2 vs 3.0).",Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232759/),,3.0,96901,DB00203,Sildenafil
,33535254,flow rate,"The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (30:70, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 254 nm at room temperature.","Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33535254/),[ml] / [min],1.0,98291,DB00203,Sildenafil
,33535254,retention times,"The retention times of sildenafil (an internal standard), and JW5624 were approximately 5.9 and 7.3 min, respectively.","Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33535254/),min,5.9,98292,DB00203,Sildenafil
,33535254,retention times,"The retention times of sildenafil (an internal standard), and JW5624 were approximately 5.9 and 7.3 min, respectively.","Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33535254/),min,7.3,98293,DB00203,Sildenafil
,33535254,detection limit,The detection limit of JW5624 in rat plasma was 0.03 μg/mL.,"Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33535254/),[μg] / [ml],0.03,98294,DB00203,Sildenafil
,33535254,F,"After p.o. administration (10 mg/kg) of JW5624, F value was approximately 71.0%.","Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33535254/),%,71.0,98295,DB00203,Sildenafil
,25581063,apparent clearance (CL/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),[l] / [h],10.8,100930,DB00203,Sildenafil
,25581063,volume (V/F),"The population mean estimates of apparent clearance (CL/F) and volume (V/F) were 10.8 l h(-1) (95% CI 9.2, 12.4 l h(-1) ) and 267 l (95% CI 208, 326 l), respectively.","Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25581063/),l,267,100931,DB00203,Sildenafil
,11879259,apparent clearance (CL/F),"For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka).",A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879259/),[l] / [h],58.5,105367,DB00203,Sildenafil
,11879259,volume of distribution (V/F),"For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka).",A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879259/),l,310,105368,DB00203,Sildenafil
,11879259,first-order absorption constant (ka),"For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka).",A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879259/),1/[h],2.6,105369,DB00203,Sildenafil
,21943935,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) for the studied analytes were within the range of 2-4 ng mL(-1) and 7.0-13.4 ng mL(-1), respectively.","High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943935/),[ng] / [ml],2-4,105374,DB00203,Sildenafil
,21943935,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) for the studied analytes were within the range of 2-4 ng mL(-1) and 7.0-13.4 ng mL(-1), respectively.","High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21943935/),[ng] / [ml],7.0-13.4,105375,DB00203,Sildenafil
>,23542722,recoveries,Dapoxetine was found to be stable in various conditions with the recoveries>87.0% (RSD <7.2%).,Determination of dapoxetine in rat plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23542722/),%,87.0,108483,DB00203,Sildenafil
,32579725,Retardation factor,"Retardation factor values were obtained as 0.22 and 0.52 for the CNZ and the IS, respectively.",Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579725/),,0.22,110226,DB00203,Sildenafil
,32579725,Retardation factor,"Retardation factor values were obtained as 0.22 and 0.52 for the CNZ and the IS, respectively.",Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579725/),,0.52,110227,DB00203,Sildenafil
,32579725,peak plasma concentration,"After oral administration, the peak plasma concentration of CNZ was obtained as 1458.01 ng/ml in 2 h.",Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32579725/),[ng] / [ml],1458.01,110228,DB00203,Sildenafil
,23884662,flow rate,Chromatographic separation was achieved on C18 column using methanol: water (85:15 v/v) as mobile phase at a flow rate of 1 ml/min and UV detection at 230 nm.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),[ml] / [min],1,110935,DB00203,Sildenafil
,23884662,retention time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,2.5,110936,DB00203,Sildenafil
,23884662,retention time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,4.0,110937,DB00203,Sildenafil
,23884662,total run time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,7,110938,DB00203,Sildenafil
,16528290,Ki,"Here we report two novel, potent, and selective PDE5 inhibitors, JNJ-10280205 and JNJ-10287069, with Ki values of 0.05 and 0.12 nM, respectively.",JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528290/),nM,0.05,117244,DB00203,Sildenafil
,16528290,Ki,"Here we report two novel, potent, and selective PDE5 inhibitors, JNJ-10280205 and JNJ-10287069, with Ki values of 0.05 and 0.12 nM, respectively.",JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16528290/),nM,0.12,117245,DB00203,Sildenafil
,26197839,clearance,"Sildenafil clearance was unaffected by hepatic pressure (clearance=0.62 L/hour/kg); however, clearance of des-methyl-sildenafil (1.94×(hepatic pressure/9)(-1.33) L/hour/kg) was predicted to decrease ~7-fold as hepatic pressure increased from 4 to 18 mmHg.",Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[l] / [h·kg],0.62,121375,DB00203,Sildenafil
,26197839,clearance,"Sildenafil clearance was unaffected by hepatic pressure (clearance=0.62 L/hour/kg); however, clearance of des-methyl-sildenafil (1.94×(hepatic pressure/9)(-1.33) L/hour/kg) was predicted to decrease ~7-fold as hepatic pressure increased from 4 to 18 mmHg.",Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[l] / [h·kg],1.94,121376,DB00203,Sildenafil
,26197839,area under the curve,Predicted drug exposure was increased by ~1.5-fold in subjects with hepatic pressures ⩾10 versus <10 mmHg (median area under the curve=533 versus 792 µg*h/L).,Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[h·μg] / [l],533,121377,DB00203,Sildenafil
,26197839,area under the curve,Predicted drug exposure was increased by ~1.5-fold in subjects with hepatic pressures ⩾10 versus <10 mmHg (median area under the curve=533 versus 792 µg*h/L).,Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26197839/),[h·μg] / [l],792,121378,DB00203,Sildenafil
,27171763,concentrations,"The median (range) sildenafil and DMS concentrations were 27.4 ng ml(-1) (2.6 to 434.0) and 105.5 ng ml(-1) (3.6 to 314.0), respectively.",An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171763/),[ng] / [ml],105.5,123221,DB00203,Sildenafil
,27171763,metabolite-to-parent ratio,The median metabolite-to-parent ratio was higher in infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs 0.7).,An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171763/),,5.2,123222,DB00203,Sildenafil
,27171763,metabolite-to-parent ratio,The median metabolite-to-parent ratio was higher in infants receiving co-medications that can induce cytochrome P450 (CYP) enzymes (5.2 vs 0.7).,An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27171763/),,0.7,123223,DB00203,Sildenafil
,32539916,total run time,The total run time for a single injection was within 10 min.,"Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539916/),min,10,123308,DB00203,Sildenafil
,28686445,oral bioavailability,"Medicinal chemistry optimization resulted in 2, which exhibits a desirable inhibitory potency of 5.6 nM with remarkable selectivity as well as excellent pharmacokinetic properties and an oral bioavailability of 63.4%.","Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28686445/),%,63.4,123336,DB00203,Sildenafil
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,11.2,131003,DB00203,Sildenafil
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,3.10,131004,DB00203,Sildenafil
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,1.50,131005,DB00203,Sildenafil
,9389342,imprecision (C.V.),"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,1.30,131006,DB00203,Sildenafil
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,13.5,131007,DB00203,Sildenafil
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,7.09,131008,DB00203,Sildenafil
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,3.69,131009,DB00203,Sildenafil
,9389342,imprecision,"The intra-batch imprecision (C.V.) of the method at plasma analyte concentrations of 1.00, 5.00, 50.0 and 200 ng/ml was 11.2, 3.10, 1.50, and 1.30%, respectively, and the corresponding inter-batch imprecision was estimated to be 13.5, 7.09, 3.69, and 5.43%.","Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9389342/),%,5.43,131010,DB00203,Sildenafil
,29278046,central,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,32.1,133382,DB00203,Sildenafil
,29278046,central,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,12.2,133383,DB00203,Sildenafil
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,32.1,133384,DB00203,Sildenafil
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,12.2,133385,DB00203,Sildenafil
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,110,133386,DB00203,Sildenafil
,29278046,peripheral volume of distribution,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,44.4,133387,DB00203,Sildenafil
,29278046,inter-compartmental clearance,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),l,44.4,133388,DB00203,Sildenafil
,29278046,inter-compartmental clearance,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],25.5,133389,DB00203,Sildenafil
,29278046,inter-compartmental clearance,"Compared to non-pregnant rabbits, the central and peripheral volume of distribution and inter-compartmental clearance of sildenafil were lower in pregnant rabbits [32.1 versus 12.2 L, 110 versus 44.4 L and 25.5 versus 12.1 L/h; all p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],12.1,133390,DB00203,Sildenafil
,29278046,formation clearance,The formation clearance from sildenafil to desmethylsildenafil was also reduced during pregnancy [13.3 versus 7.8 L/h; p < 0.05].,Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],13.3,133391,DB00203,Sildenafil
,29278046,formation clearance,The formation clearance from sildenafil to desmethylsildenafil was also reduced during pregnancy [13.3 versus 7.8 L/h; p < 0.05].,Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),[l] / [h],7.8,133392,DB00203,Sildenafil
,29278046,elimination clearance,"3. In contrast, the elimination clearance of desmethylsildenafil, was higher in pregnancy [73.5 versus 116. 9; p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),,73.5,133393,DB00203,Sildenafil
,29278046,elimination clearance,"3. In contrast, the elimination clearance of desmethylsildenafil, was higher in pregnancy [73.5 versus 116. 9; p < 0.05].",Pregnancy affects the pharmacokinetics of sildenafil and its metabolite in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29278046/),,116. 9,133394,DB00203,Sildenafil
,21781653,C(max),"The geometric means, C(max), of the reference and the test formulations were 696.42 and 734.06 ng/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[ng] / [ml],696.42,134237,DB00203,Sildenafil
,21781653,C(max),"The geometric means, C(max), of the reference and the test formulations were 696.42 and 734.06 ng/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[ng] / [ml],734.06,134238,DB00203,Sildenafil
,21781653,AUC(0-t),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,073.03",134239,DB00203,Sildenafil
,21781653,AUC(0-t),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,237.37",134240,DB00203,Sildenafil
,21781653,AUC(0-t),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"1,950.26",134241,DB00203,Sildenafil
,21781653,AUC(0-inf),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,237.37",134242,DB00203,Sildenafil
,21781653,AUC(0-inf),"The mean values of the AUC(0-t) and AUC(0-inf) of the test formulation were 2,073.03 and 2,237.37 ng × h/ml, while those of the reference formulation were 1,950.26 and 2,078.06 ng × h/ml.",Comparative bioavailability of two sildenafil tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21781653/),[h·ng] / [ml],"2,078.06",134243,DB00203,Sildenafil
less,22010981,friability,"The sildenafil lactate-loaded orally disintegrating tablet prepared with 45 mg/tab of menthol and 1.5 mg/tab of colloidal silica gave a hardness of 3-4 KP, friability less than 0.5% and disintegration time less than 30 s, suggesting that it was a practical and commercial product with good tablet property and excellent efficacy.",Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010981/),%,0.5,137720,DB00203,Sildenafil
less,22010981,disintegration time,"The sildenafil lactate-loaded orally disintegrating tablet prepared with 45 mg/tab of menthol and 1.5 mg/tab of colloidal silica gave a hardness of 3-4 KP, friability less than 0.5% and disintegration time less than 30 s, suggesting that it was a practical and commercial product with good tablet property and excellent efficacy.",Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010981/),s,30,137721,DB00203,Sildenafil
,25400284,flow rate,"Chromatographic separation was performed on a Thermo Scientific Accucore C18 column with an isocratic mobile phase composed of 0.1% v/v formic acid in purified water-methanol (20:80, v/v), at a flow rate of 0.3 mL/min.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ml] / [min],0.3,138803,DB00203,Sildenafil
,25400284,AUC0-t,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[h·ng] / [ml],2285.79,138804,DB00203,Sildenafil
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ng] / [ml],726.10,138805,DB00203,Sildenafil
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[h·ng] / [ml],2363.25,138806,DB00203,Sildenafil
,25400284,Cmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),[ng] / [ml],713.91,138807,DB00203,Sildenafil
,25400284,Tmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),h,0.94,138808,DB00203,Sildenafil
,25400284,Tmax,"AUC0-t , Cmax and Tmax were 2285.79 ng h/mL, 726.10 ng/mL and 0.94 h for Viagra and 2363.25 ng h/mL, 713.91 ng/mL and 0.83 hour for Edyfil.",Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400284/),h,0.83,138809,DB00203,Sildenafil
,15224134,IC50,Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM.,"Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),nM,0.7,138838,DB00203,Sildenafil
,15224134,Tmax,"Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h.","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,1,138839,DB00203,Sildenafil
,15224134,T1/2,"Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects have been observed after 7 h.","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,1.2,138840,DB00203,Sildenafil
,15224134,Tmax,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),min,40,138841,DB00203,Sildenafil
,15224134,T1/2,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),h,4,138842,DB00203,Sildenafil
,15224134,absolute bioavailability,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),%,14.5,138843,DB00203,Sildenafil
,15224134,absolute bioavailability,"In humans, vardenafil is rapidly absorbed (Tmax approximately 40 min) and more slowly metabolized (T1/2 approximately 4 h), with an absolute bioavailability of 14.5% (vs 40% for sildenafil).","Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15224134/),%,40,138844,DB00203,Sildenafil
,28561239,flow rate,"The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (35:65, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 280 nm at room temperature.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),[ml] / [min],1.0,141985,DB00203,Sildenafil
,28561239,retention times,"The retention times of sildenafil (an internal standard), and fenofibric acid were approximately 5.9 and 7.7 min, respectively.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),min,5.9,141986,DB00203,Sildenafil
,28561239,retention times,"The retention times of sildenafil (an internal standard), and fenofibric acid were approximately 5.9 and 7.7 min, respectively.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),min,7.7,141987,DB00203,Sildenafil
,28561239,relative bioavailability,"After oral administration (20 mg/kg) of JW322, relative bioavailability was approximately 272.8% compared to fenofibrate.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),%,272.8,141988,DB00203,Sildenafil
,14603504,absolute oral bioavailability (F),The extent of absolute oral bioavailability (F) of DA-8159 was 38.0% at a dose of 30 mg/kg.,"Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),%,38.0,143731,DB00203,Sildenafil
,14603504,AUCs,"The AUCs were not significantly different between intragastric and intraduodenal administration of DA-8159 at a dose of 30 mg/kg (131 and 127 microg x min/mL), suggesting that gastric first-pass effect of DA-8159 was almost negligible in rats.","Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),[min·μg] / [ml],131,143732,DB00203,Sildenafil
,14603504,AUCs,"The AUCs were not significantly different between intragastric and intraduodenal administration of DA-8159 at a dose of 30 mg/kg (131 and 127 microg x min/mL), suggesting that gastric first-pass effect of DA-8159 was almost negligible in rats.","Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),[min·μg] / [ml],127,143733,DB00203,Sildenafil
,24447534,Tmax,"Mean Cmax was reduced by 59%, and median Tmax was delayed from 0.625 hour (fasting) to 4 hours (high-fat meal).",Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447534/),h,0.625,145915,DB00203,Sildenafil
,24447534,Tmax,"Mean Cmax was reduced by 59%, and median Tmax was delayed from 0.625 hour (fasting) to 4 hours (high-fat meal).",Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24447534/),h,4,145916,DB00203,Sildenafil
≈,33704925,absolute bioavailability,"Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%.","Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704925/),%,60,147401,DB00203,Sildenafil
,15200445,extent of drug bound to plasma protein,The average extent of drug bound to plasma protein was approximately 96% in hemodialysis patients.,The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200445/),%,96,148157,DB00203,Sildenafil
,19843000,time,"There was no difference in time from randomisation to delivery in the two treatment groups, with a median time of 4 days (range 1-15) in the sildenafil group and 4.5 days (range 1-30) in the placebo group.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),d,4,150023,DB00203,Sildenafil
,19843000,time,"There was no difference in time from randomisation to delivery in the two treatment groups, with a median time of 4 days (range 1-15) in the sildenafil group and 4.5 days (range 1-30) in the placebo group.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),d,4.5,150024,DB00203,Sildenafil
,19843000,maximum drug concentrations,"Sildenafil achieved maximum drug concentrations of 48 ng/ml, 88 ng/ml, and 271 ng/ml after 3 days of 20 mg, 40 mg and 80 mg tid, respectively.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),[ng] / [ml],48,150025,DB00203,Sildenafil
,19843000,maximum drug concentrations,"Sildenafil achieved maximum drug concentrations of 48 ng/ml, 88 ng/ml, and 271 ng/ml after 3 days of 20 mg, 40 mg and 80 mg tid, respectively.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),[ng] / [ml],88,150026,DB00203,Sildenafil
,19843000,maximum drug concentrations,"Sildenafil achieved maximum drug concentrations of 48 ng/ml, 88 ng/ml, and 271 ng/ml after 3 days of 20 mg, 40 mg and 80 mg tid, respectively.","A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843000/),[ng] / [ml],271,150027,DB00203,Sildenafil
,28871716,Cmax,"Pre-administration of Eruca sativa has increased Sildenafil Cmax from 226.72 to 345.25 ng/ml, (p<0.05).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [ml],226.72,152396,DB00203,Sildenafil
,28871716,Cmax,"Pre-administration of Eruca sativa has increased Sildenafil Cmax from 226.72 to 345.25 ng/ml, (p<0.05).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [ml],345.25,152397,DB00203,Sildenafil
,28871716,AUC,"In addition, the AUC of Sildenafil has significantly increased when it was pre-administered with Eruca sativa (550.59 vs. 916.48 ng/ml*hr).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [h·ml],550.59,152398,DB00203,Sildenafil
,28871716,AUC,"In addition, the AUC of Sildenafil has significantly increased when it was pre-administered with Eruca sativa (550.59 vs. 916.48 ng/ml*hr).",The influence of Eruca sativa (Arugula) on pharmacokinetics of Sildenafil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28871716/),[ng] / [h·ml],916.48,152399,DB00203,Sildenafil
,11597545,elimination half-life,The elimination half-life was prolonged (4.7 hours compared with 3 hours in healthy volunteers).,Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,4.7,153703,DB00203,Sildenafil
,11597545,elimination half-life,The elimination half-life was prolonged (4.7 hours compared with 3 hours in healthy volunteers).,Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,3,153704,DB00203,Sildenafil
,11597545,half-life,"The area under the concentration-time data for UK was about threefold larger than in healthy volunteers, and the half-life was prolonged from 3.8 hours to 11.4 hours.",Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,3.8,153705,DB00203,Sildenafil
,11597545,half-life,"The area under the concentration-time data for UK was about threefold larger than in healthy volunteers, and the half-life was prolonged from 3.8 hours to 11.4 hours.",Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,11.4,153706,DB00203,Sildenafil
,15881813,retention time,The retention time of I.S and sildenafil were 5.5 minutes and 7.2 minutes respectively.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),min,5.5,153718,DB00203,Sildenafil
,15881813,retention time,The retention time of I.S and sildenafil were 5.5 minutes and 7.2 minutes respectively.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),min,7.2,153719,DB00203,Sildenafil
,15881813,extraction efficiency,The extraction efficiency from plasma varied from 79.69% to 81.13 %.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),%,79.69,153720,DB00203,Sildenafil
,15881813,extraction efficiency,The extraction efficiency from plasma varied from 79.69% to 81.13 %.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),%,81.13,153721,DB00203,Sildenafil
,15881813,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/ml.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),[ng] / [ml],10,153722,DB00203,Sildenafil
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),[μg] / [min],80,158142,DB00203,Sildenafil
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),[μg] / [min],160,158143,DB00203,Sildenafil
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),,77,158144,DB00203,Sildenafil
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),,127,158145,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,97.10,158516,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,91.43,158517,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,97.09,158518,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,91.43,158519,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,03,158520,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,82.25,158521,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,101,158522,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,90.90,158523,DB00203,Sildenafil
,32463593,Relative bioavailability,"Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUClast , Cmax , and AUCinf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively).",Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32463593/),%,103.71,158524,DB00203,Sildenafil
,23470352,bioavailability,"Moreover, the in vivo study showed that the AUC₀₋₁₂ of lyophilized tablets was significantly higher than that of directly compressed tablets, with bioavailability values of 159.81 and 140.85%, respectively, compared to the commercial oral product.",An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23470352/),%,159.81,163190,DB00203,Sildenafil
,23470352,bioavailability,"Moreover, the in vivo study showed that the AUC₀₋₁₂ of lyophilized tablets was significantly higher than that of directly compressed tablets, with bioavailability values of 159.81 and 140.85%, respectively, compared to the commercial oral product.",An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23470352/),%,140.85,163191,DB00203,Sildenafil
>,19333762,solubility,"The targeted solubility (>20 mg/ml) of sildenafil citrate was achieved with cosolvent systems S1, S3, and S5 and with microemulsion systems ME3-ME6.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],20,163937,DB00203,Sildenafil
,19333762,saturated solubility,"The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],22.98,163938,DB00203,Sildenafil
,19333762,saturated solubility,"The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[mg] / [ml],23.79,163939,DB00203,Sildenafil
,19333762,t (max),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),h,0.75,163940,DB00203,Sildenafil
,19333762,AUC((0-infinity)),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[h·ng] / [ml],"1,412.42",163941,DB00203,Sildenafil
,19333762,t (max),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),h,1.25,163942,DB00203,Sildenafil
,19333762,AUC((0-infinity)),"Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg.",Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),[h·ng] / [ml],"1,251.14",163943,DB00203,Sildenafil
,19333762,relative bioavailability,The relative bioavailability was 112.89%.,Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19333762/),%,112.89,163944,DB00203,Sildenafil
,24918347,flow rate,"The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (45:55, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 254 nm at room temperature.",Determination of SK3497 in rat plasma and its application in a pharmacokinetic study of SK3497. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24918347/),[ml] / [min],1.0,167265,DB00203,Sildenafil
,24918347,retention times,"The retention times of sildenafil (an internal standard), and SK3497 were approximately 5.6 and 8.3 min, respectively.",Determination of SK3497 in rat plasma and its application in a pharmacokinetic study of SK3497. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24918347/),min,5.6,167266,DB00203,Sildenafil
,24918347,retention times,"The retention times of sildenafil (an internal standard), and SK3497 were approximately 5.6 and 8.3 min, respectively.",Determination of SK3497 in rat plasma and its application in a pharmacokinetic study of SK3497. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24918347/),min,8.3,167267,DB00203,Sildenafil
,24918347,detection limit,The detection limit of SK3497 in rat plasma was 0.03 μg/mL.,Determination of SK3497 in rat plasma and its application in a pharmacokinetic study of SK3497. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24918347/),[μg] / [ml],0.03,167268,DB00203,Sildenafil
,24918347,F-,"After p.o. administration (30 mg/kg) of SK3497, F-value was approximately 53.0%.",Determination of SK3497 in rat plasma and its application in a pharmacokinetic study of SK3497. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24918347/),%,53.0,167269,DB00203,Sildenafil
,26987948,onset of action,"At a 0.5-mg dose, the mean onset of action was 1.3 ± 0.6 min and lasted for about 1.5 h according to the pharmacokinetic studies.",Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26987948/),min,1.3,167772,DB00203,Sildenafil
,21425954,solubility,"Sildenafil displayed a high solubility of 124 mg/mL in the microemulsion consisting of 40% oleic acid, 10% H(2)O, and 50% Tween 80:ethanol (EA) (at a 1:4 weight ratio).",Rapid-onset sildenafil nasal spray carried by microemulsion systems: in vitro evaluation and in vivo pharmacokinetic studies in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21425954/),[mg] / [ml],124,169246,DB00203,Sildenafil
,18972873,flow rate,"The separation was achieved on a monolithic silica column using acetonitrile-potassium dihydrogen phosphate buffer (25:75,v/v), pH 3.0, as the mobile phase at a flow rate of 1.5 ml min(-1).",A rapid high-performance liquid chromatographic method for the determination of pantoprazole in plasma using UV detection. Application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18972873/),[ml] / [min],1.5,176276,DB00203,Sildenafil
,29679708,Mean dissolution time (MDT),"Mean dissolution time (MDT) from tablets made of HPMC, carbomer or a mixture of HPMC and sodium alginate (2:1) was ca. 100 min, which was more than twelve times longer as compared to matrices prepared of silicified microcrystalline cellulose (MDT = 8 min).",The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),min,100,176515,DB00203,Sildenafil
,29679708,MDT,"Mean dissolution time (MDT) from tablets made of HPMC, carbomer or a mixture of HPMC and sodium alginate (2:1) was ca. 100 min, which was more than twelve times longer as compared to matrices prepared of silicified microcrystalline cellulose (MDT = 8 min).",The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),min,8,176516,DB00203,Sildenafil
,29679708,tmax,Sustained release of sildenafil from ground carbomer tablets reflected in the slow absorption of the drug (tmax = 5.0 ± 1.2 h) in vivo and the relative bioavailability of 151%.,The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),h,5.0,176517,DB00203,Sildenafil
,29679708,relative bioavailability,Sustained release of sildenafil from ground carbomer tablets reflected in the slow absorption of the drug (tmax = 5.0 ± 1.2 h) in vivo and the relative bioavailability of 151%.,The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679708/),%,151,176518,DB00203,Sildenafil
,15315772,m/z,"The mass transitions m/z 390.4 --> 268.0 and m/z 475.5 --> 58.3 were used to measure I and II, respectively.",Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315772/),,390.4,178821,DB00203,Sildenafil
,15315772,m/z,"The mass transitions m/z 390.4 --> 268.0 and m/z 475.5 --> 58.3 were used to measure I and II, respectively.",Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315772/),,268.0,178822,DB00203,Sildenafil
,15315772,m/z,"The mass transitions m/z 390.4 --> 268.0 and m/z 475.5 --> 58.3 were used to measure I and II, respectively.",Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315772/),,475.5,178823,DB00203,Sildenafil
,15315772,m/z,"The mass transitions m/z 390.4 --> 268.0 and m/z 475.5 --> 58.3 were used to measure I and II, respectively.",Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315772/),,58.3,178824,DB00203,Sildenafil
,15315772,linear dynamic,The assay exhibited a linear dynamic range of 10-1000 ng/mL for tadalafil in human plasma.,Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315772/),[ng] / [ml],10-1000,178825,DB00203,Sildenafil
,15315772,Run time,Run time of 1.2 min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,Quantitation of tadalafil in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315772/),min,1.2,178826,DB00203,Sildenafil
,27779776,AUC∞,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),[h·ng] / [ml],537,182986,DB00203,Sildenafil
,27779776,Cmax,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),[ng] / [ml],189.4,182987,DB00203,Sildenafil
,27779776,t1/2,"For a dose of 10 mg administered as a bolus followed by 2.5 mg administered over 2 h the results were AUC∞ 537 ng h ml-1 , Cmax 189.4 ng ml-1 and t1/2 10.5 h.","A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779776/),h,10.5,182988,DB00203,Sildenafil
,16369998,oral bioavailability,Its oral bioavailability is about 40%.,Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),%,40,184914,DB00203,Sildenafil
,16369998,permeability area,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],0.0101,184915,DB00203,Sildenafil
,16369998,permeability area,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],0.,184916,DB00203,Sildenafil
,16369998,permeability area,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],0,184917,DB00203,Sildenafil
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),[ml] / [cm·min],68.0,184918,DB00203,Sildenafil
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),,32.3,184919,DB00203,Sildenafil
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),,23.0,184920,DB00203,Sildenafil
,16369998,percentage absorbed,"The values of the permeability area product normalized to segment length (ml/min.cm) were 0.0101, 0.0063, 0.0059 and 0.0023 and those of the percentage absorbed were 68.0, 32.3, 23.0 and 5.0 in jejunoileum, duodenum, ascending colon and rectum, respectively.",Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16369998/),,5.0,184921,DB00203,Sildenafil
,25864807,flow rate,"Chromatographic separation was achieved on a cyanopropyl bonded-phase column with a mobile phase composed of 50 m m potassium dihydrogen phosphate buffer (pH 4.5) and acetonitrile (75:25, v/v), pumped at the flow rate of 1 mL/min.",Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),[ml] / [min],1,192029,DB00203,Sildenafil
,25864807,limit of detection,The limit of detection was 5 ng/mL.,Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),[ng] / [ml],5,192030,DB00203,Sildenafil
,25864807,recovery,The recovery of sildenafil was 85.22 ± 4.54%.,Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864807/),%,85.22,192031,DB00203,Sildenafil
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,8,193385,DB00203,Sildenafil
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,28,193386,DB00203,Sildenafil
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,5,193387,DB00203,Sildenafil
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,23,193388,DB00203,Sildenafil
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,15,193389,DB00203,Sildenafil
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,3,193390,DB00203,Sildenafil
,33517421,V:V,"The protein precipitation was used for extraction and the gradient elution of the mobile phase A of water (containing 0.01% formic acid) and the mobile phase B of acetonitrile, and methanol (V:V = 1:1, containing 0.01% formic acid) was used for chromatographic separation on a C18 column.",UPLC-MS/MS for the Simultaneous Determination of Sildenafil and N-Desmethyl Sildenafil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33517421/),,1:1,196209,DB00203,Sildenafil
,34199328,AUC0-t,"The exposure of sildenafil (AUC0-t) showed a statistically significant increase in cigarette smokers (1156 ± 542 ng·h/mL) of 61% (p < 0.05) while in cannabis smokers (967 ± 262 ng·h/mL), a non-significant increase in AUC0-t of 35% (p > 0.05) was observed relative to non-smokers (717 ± 311 ng·h/mL).",Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34199328/),[h·ng] / [ml],1156,196222,DB00203,Sildenafil
,34199328,AUC0-t,"The exposure of sildenafil (AUC0-t) showed a statistically significant increase in cigarette smokers (1156 ± 542 ng·h/mL) of 61% (p < 0.05) while in cannabis smokers (967 ± 262 ng·h/mL), a non-significant increase in AUC0-t of 35% (p > 0.05) was observed relative to non-smokers (717 ± 311 ng·h/mL).",Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34199328/),[h·ng] / [ml],967,196223,DB00203,Sildenafil
,34199328,AUC0-t,"The exposure of sildenafil (AUC0-t) showed a statistically significant increase in cigarette smokers (1156 ± 542 ng·h/mL) of 61% (p < 0.05) while in cannabis smokers (967 ± 262 ng·h/mL), a non-significant increase in AUC0-t of 35% (p > 0.05) was observed relative to non-smokers (717 ± 311 ng·h/mL).",Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34199328/),[h·ng] / [ml],717,196224,DB00203,Sildenafil
,19042162,flow rate,"Chromatographic separation was carried on a Luna C(18) column (50 mm x 2.0 mm, 3 microm) at 40 degrees C, with an isocratic mobile phase consisting of 10 mM ammonium acetate (pH 5.0) and acetonitrile (10:90, v/v), a flow rate of 0.2 mL/min, and a total run time of 2 min.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),[ml] / [min],0.2,196427,DB00203,Sildenafil
,19042162,total run time,"Chromatographic separation was carried on a Luna C(18) column (50 mm x 2.0 mm, 3 microm) at 40 degrees C, with an isocratic mobile phase consisting of 10 mM ammonium acetate (pH 5.0) and acetonitrile (10:90, v/v), a flow rate of 0.2 mL/min, and a total run time of 2 min.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),min,2,196428,DB00203,Sildenafil
,19042162,m,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,489.1,196429,DB00203,Sildenafil
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,460.9,196430,DB00203,Sildenafil
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,151.2,196431,DB00203,Sildenafil
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,475.3,196432,DB00203,Sildenafil
,19042162,m/z,"Detection and quantification were performed using a mass spectrometer in the selected reaction-monitoring mode with positive electrospray ionization at m/z 489.1-->151.2 for vardenafil, m/z 460.9-->151.2 for N-desethylvardenafil, and m/z 475.3-->100.1 for the internal standard (IS), respectively.","Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of vardenafil and its major metabolite, N-desethylvardenafil, in human plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042162/),,100.1,196433,DB00203,Sildenafil
,26253809,recovery,The mean recovery was 83.2 % for sildenafil and 84.5% for N-desmethyl sildenafil.,Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253809/),%,83.2,197172,DB00203,Sildenafil
,26253809,recovery,The mean recovery was 83.2 % for sildenafil and 84.5% for N-desmethyl sildenafil.,Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26253809/),%,84.5,197173,DB00203,Sildenafil
,30299299,Cmax,"Sildenafil Cmax (156.8 ± 124.5 ng/ml) was elevated in 66% of patients, with a two to fivefold increase over the upper limit of the reference range in 25% of patients.",Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299299/),[ng] / [ml],156.8,197772,DB00203,Sildenafil
,30299299,Cmax,"Metabolite Cmax (133.3 ± 102.0 ng/ml) was elevated in 75% of patients, with a three to sevenfold increase over the upper limit of the reference range in 40% of patients.",Pharmacokinetics of Sildenafil in Patients with a Left Ventricular Assist Device: A Word of Caution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299299/),[ng] / [ml],133.3,197773,DB00203,Sildenafil
,10546851,area under the concentration curve for 0-8 h (AUC0-8h),"The geometric mean area under the concentration curve for 0-8 h (AUC0-8h) and maximum plasma concentration (Cmax) for indinavir were 19.69 microg/ml h (range, 9.19-31.99 microg/ml h) and 7.02 microg/ml (range, 2.33-16.17 microg/ml), respectively, on the first study day.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [h·ml],19.69,197867,DB00203,Sildenafil
,10546851,maximum plasma concentration (Cmax),"The geometric mean area under the concentration curve for 0-8 h (AUC0-8h) and maximum plasma concentration (Cmax) for indinavir were 19.69 microg/ml h (range, 9.19-31.99 microg/ml h) and 7.02 microg/ml (range, 2.33-16.17 microg/ml), respectively, on the first study day.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [ml],7.02,197868,DB00203,Sildenafil
,10546851,AUC0-8h,"In the presence of sildenafil, the mean AUC0-8h and Cmax of indinavir were 22.37 microg/ml h [range, 10.08-37.25 microg/ml h; 95% confidence interval (CI) for difference between means, -15 to 13.25) and 9.11 microg/ml (range, 3.41-22.78 microg/ml; 95% CI, -13 to 6.37), respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [h·ml],22.37,197869,DB00203,Sildenafil
,10546851,Cmax,"In the presence of sildenafil, the mean AUC0-8h and Cmax of indinavir were 22.37 microg/ml h [range, 10.08-37.25 microg/ml h; 95% confidence interval (CI) for difference between means, -15 to 13.25) and 9.11 microg/ml (range, 3.41-22.78 microg/ml; 95% CI, -13 to 6.37), respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[μg] / [ml],9.11,197870,DB00203,Sildenafil
,10546851,AUC0-8h,"The geometric mean AUC0-8h and Cmax for sildenafil were 1631 ng/ml h (range, 643-2970 ng/ml h) and 384 ng/ml (range, 209-766 ng/ml) respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[ng] / [h·ml],1631,197871,DB00203,Sildenafil
,10546851,Cmax,"The geometric mean AUC0-8h and Cmax for sildenafil were 1631 ng/ml h (range, 643-2970 ng/ml h) and 384 ng/ml (range, 209-766 ng/ml) respectively.",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),[ng] / [ml],384,197872,DB00203,Sildenafil
,10546851,concentration producing 50% inhibition of control enzyme activity (IC50),"Indinavir was a potent inhibitor of sildenafil hepatic metabolism in vitro [concentration producing 50% inhibition of control enzyme activity (IC50) = 0.39 +/- 0.17 microM, mean +/- SD].",Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546851/),μM,0.39,197873,DB00203,Sildenafil
,21383523,CL/F,"The final population mean values of CL/F and k were estimated to be 0.409 · (1 - 0.0377 · (AGE - 3.81)) · WT L/h and 0.175 h(-1), respectively.",Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383523/),,0.409,197956,DB00203,Sildenafil
,21383523,k,"The final population mean values of CL/F and k were estimated to be 0.409 · (1 - 0.0377 · (AGE - 3.81)) · WT L/h and 0.175 h(-1), respectively.",Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383523/),1/[h],0.175,197957,DB00203,Sildenafil
,11992097,minimum effective dose,The minimum effective dose for complete erection was 10 mcg.,"The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11992097/),mcg,10,201650,DB00203,Sildenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],157,203031,DB00203,Sildenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],103,203032,DB00203,Sildenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],215,203033,DB00203,Sildenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],141,203034,DB00203,Sildenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],125,203035,DB00203,Sildenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],200,203036,DB00203,Sildenafil
,28791664,maximal concentration (Cmax),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),[ng] / [ml],366,205953,DB00203,Sildenafil
,28791664,time to maximal concentration,"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),h,0.92,205954,DB00203,Sildenafil
,28791664,elimination half-life (t1/2),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),h,2.41,205955,DB00203,Sildenafil
,28791664,total clearance (CLtot/F),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),[l] / [h],5.85,205956,DB00203,Sildenafil
,28791664,volume of distribution (Vd/F),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),l,20.13,205957,DB00203,Sildenafil
,28791664,absorption rate constants (Ka),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),1/[h],0.343,205958,DB00203,Sildenafil
,28791664,elimination rate (Ke),"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),1/[h],0.35,205959,DB00203,Sildenafil
,28791664,area under curve from zero to infinity,"The following pharmacokinetic parameters were obtained: maximal concentration (Cmax): 366±179 ng/mL, time to maximal concentration: 0.92±0.30 hours, elimination half-life (t1/2): 2.41±1.18 hours, total clearance (CLtot/F): 5.85±2.81 L/hour, volume of distribution (Vd/F): 20.13±14.5 L, absorption rate constants (Ka): 0.343 hour-1, elimination rate (Ke): 0.35 hour-1, area under curve from zero to infinity: 2061±618 ng/mL/hour.",Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791664/),[ng] / [h·ml],2061,205960,DB00203,Sildenafil
,19830413,maximum plasma concentration (C(max)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[ng] / [ml],212.44,206686,DB00203,Sildenafil
,19830413,maximum plasma concentration (C(max)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[ng] / [ml],134.07,206687,DB00203,Sildenafil
,19830413,area under the plasma concentration time curve from zero to infinity (AUC(infinity)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[h·ng] / [ml],564.51,206688,DB00203,Sildenafil
,19830413,area under the plasma concentration time curve from zero to infinity (AUC(infinity)),"Study results showed that pummelo juice reduced the rate and extent of sildenafil bioavailability to around 60% [maximum plasma concentration (C(max)); from 212.44 ng/ml to 134.07 ng/ml, 90% confidence interval (90% CI) 44.70-89.11, and area under the plasma concentration time curve from zero to infinity (AUC(infinity)); from 564.51 ng.hr/ml to 336.87 ng.hr/ml, 90% CI 39.17-90.92].",The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19830413/),[h·ng] / [ml],336.87,206689,DB00203,Sildenafil
,24786013,Cmax,"The geometric mean (CV%) for Cmax in the OSF and FCT formulations were 267.21 (4.68%) ng/mL and 285.97 (5.32%) ng/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[ng] / [ml],267.21,208882,DB00203,Sildenafil
,24786013,Cmax,"The geometric mean (CV%) for Cmax in the OSF and FCT formulations were 267.21 (4.68%) ng/mL and 285.97 (5.32%) ng/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[ng] / [ml],285.97,208883,DB00203,Sildenafil
,24786013,AUClast,"The geometric mean for AUClast in the OSF and FCT formulations were 664.48 (4.40%) ng x h/mL and 647.96 (4.63%) ng x h/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],664.48,208884,DB00203,Sildenafil
,24786013,AUClast,"The geometric mean for AUClast in the OSF and FCT formulations were 664.48 (4.40%) ng x h/mL and 647.96 (4.63%) ng x h/mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],647.96,208885,DB00203,Sildenafil
,24786013,AUCinf,"The geometric mean for AUCinf in the OSF and FCT formulations were 685.65 (4.37%) ng x h/mL and 666.28 (4.60%) ng x h/ mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],685.65,208886,DB00203,Sildenafil
,24786013,AUCinf,"The geometric mean for AUCinf in the OSF and FCT formulations were 685.65 (4.37%) ng x h/mL and 666.28 (4.60%) ng x h/ mL, respectively.",Pharmacokinetics of a new orally soluble film formulation of sildenafil administered without water. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786013/),[h·ng] / [ml],666.28,208887,DB00203,Sildenafil
,16920325,limit of quantitation (LOQ),Sampling lasted for 24h after dosing; consequently a limit of quantitation (LOQ) of 7.858 ng/mL was achieved for sildenafil whereas a LOQ of 8.675 ng/mL was obtained for N-desmethyl sildenafil.,Simultaneous determination of sildenafil and N-desmethyl sildenafil in human plasma by high-performance liquid chromatography method using electrochemical detection with application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920325/),[ng] / [ml],7.858,209282,DB00203,Sildenafil
,16920325,LOQ,Sampling lasted for 24h after dosing; consequently a limit of quantitation (LOQ) of 7.858 ng/mL was achieved for sildenafil whereas a LOQ of 8.675 ng/mL was obtained for N-desmethyl sildenafil.,Simultaneous determination of sildenafil and N-desmethyl sildenafil in human plasma by high-performance liquid chromatography method using electrochemical detection with application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920325/),[ng] / [ml],8.675,209283,DB00203,Sildenafil
,25874072,Cthrough,"The patient had a sildenafil Cthrough and Cmax of 276.94 ng/mL and 1733.19 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],276.94,209788,DB00203,Sildenafil
,25874072,Cmax,"The patient had a sildenafil Cthrough and Cmax of 276.94 ng/mL and 1733.19 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],1733.19,209789,DB00203,Sildenafil
,25874072,Cthrough,"The Cthrough and the Cmax of bosentan were 1546.53 ng/mL and 3365.99 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],1546.53,209790,DB00203,Sildenafil
,25874072,Cmax,"The Cthrough and the Cmax of bosentan were 1546.53 ng/mL and 3365.99 ng/mL, respectively.",Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25874072/),[ng] / [ml],3365.99,209791,DB00203,Sildenafil
greater,26688342,recovery,The recovery of sildenafil was greater than 78.4%.,Sensitive and rapid HPLC-UV method with back-extraction step for the determination of sildenafil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26688342/),%,78.4,212098,DB00203,Sildenafil
,23781859,content uniformity,"The mean weight variation, content uniformity, hardness and disintegration time of the prepared SVS were 1.127 ± 0.020 g, 98.25 ± 2.50%, 2.5 ± 0.08 kg and 9 ± 1.0 min, respectively.","Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781859/),kg,2.5,212437,DB00203,Sildenafil
,23781859,disintegration time,"The mean weight variation, content uniformity, hardness and disintegration time of the prepared SVS were 1.127 ± 0.020 g, 98.25 ± 2.50%, 2.5 ± 0.08 kg and 9 ± 1.0 min, respectively.","Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23781859/),min,9,212438,DB00203,Sildenafil
,11879256,t1/2,"In the elderly, AUC values were approximately twice as high and Cmax values 60--70% higher than those for young men, while t1/2 values were approximately 1 h longer for sildenafil and 2 h longer for UK-103,320.",The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879256/),h,1,212965,DB00203,Sildenafil
,11879256,t1/2,"In the elderly, AUC values were approximately twice as high and Cmax values 60--70% higher than those for young men, while t1/2 values were approximately 1 h longer for sildenafil and 2 h longer for UK-103,320.",The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879256/),h,2,212966,DB00203,Sildenafil
,15823634,plasma levels,"Sildenafil plasma levels 1 h after a 0.5, 1.0 and 2 mg/kg dose of Sildenafil were 109+/-87, 150+/-62 and 368+/-200 ng/ml, respectively.",Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823634/),[ng] / [ml],109,217515,DB00203,Sildenafil
,15823634,plasma levels,"Sildenafil plasma levels 1 h after a 0.5, 1.0 and 2 mg/kg dose of Sildenafil were 109+/-87, 150+/-62 and 368+/-200 ng/ml, respectively.",Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823634/),[ng] / [ml],150,217516,DB00203,Sildenafil
,15823634,plasma levels,"Sildenafil plasma levels 1 h after a 0.5, 1.0 and 2 mg/kg dose of Sildenafil were 109+/-87, 150+/-62 and 368+/-200 ng/ml, respectively.",Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823634/),[ng] / [ml],368,217517,DB00203,Sildenafil
,10219969,Tmax,"With the exception of male rat, Tmax occurred at approximately 1 h or less.","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,1,221877,DB00203,Sildenafil
,10219969,volume of distribution,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),[l] / [kg],1-2,221878,DB00203,Sildenafil
,10219969,volume of distribution,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),[l] / [kg],5.2,221879,DB00203,Sildenafil
,10219969,plasma protein binding,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),%,84,221880,DB00203,Sildenafil
,10219969,plasma protein binding,"3. The volume of distribution was similar in rodents and humans (1-2 l/kg) but was greater in dog (5.2 l/kg), due to lower plasma protein binding (84 versus 94-96% respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),%,94-96,221881,DB00203,Sildenafil
,10219969,elimination half-lives,"4. High clearance was the principal determinant of short elimination half-lives in rodents (0.4-1.3 h), whereas moderate clearance in dog and man resulted in longer half-lives (6.1 and 3.7 h respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,0.4-1.3,221882,DB00203,Sildenafil
,10219969,half-lives,"4. High clearance was the principal determinant of short elimination half-lives in rodents (0.4-1.3 h), whereas moderate clearance in dog and man resulted in longer half-lives (6.1 and 3.7 h respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,6.1,221883,DB00203,Sildenafil
,10219969,half-lives,"4. High clearance was the principal determinant of short elimination half-lives in rodents (0.4-1.3 h), whereas moderate clearance in dog and man resulted in longer half-lives (6.1 and 3.7 h respectively).","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),h,3.7,221884,DB00203,Sildenafil
,10219969,AUC(infinity),"Following oral doses, AUC(infinity) for the piperazine N-desmethyl and piperazine N,N'-desethyl metabolites were 55 and 27% that of parent compound respectively.","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),,55,221885,DB00203,Sildenafil
,10219969,AUC(infinity),"Following oral doses, AUC(infinity) for the piperazine N-desmethyl and piperazine N,N'-desethyl metabolites were 55 and 27% that of parent compound respectively.","Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10219969/),,27,221886,DB00203,Sildenafil
,25624751,bioavailability,"Second, the drug undergoes extensive first-pass metabolism, resulting in a low (40%) bioavailability.","Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),%,40,226392,DB00203,Sildenafil
,25624751,wetting time,"The tablet contained 8% soy polysaccharide as a superdisintegrant and provided a wetting time of 25 seconds, and in vitro dispersion times of 55 seconds.","Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),seconds,25,226393,DB00203,Sildenafil
,25624751,dispersion times,"The tablet contained 8% soy polysaccharide as a superdisintegrant and provided a wetting time of 25 seconds, and in vitro dispersion times of 55 seconds.","Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),seconds,55,226394,DB00203,Sildenafil
,25624751,drug release,The drug release was found to be 95.6%.,"Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25624751/),%,95.6,226395,DB00203,Sildenafil
,33012742,maximum plasma concentrations,The maximum plasma concentrations of SIL after administration varied in range from 7.8 to 101.0 ng/mL.,The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),[ng] / [ml],7.8 to 101.0,227800,DB00203,Sildenafil
,33012742,Cmax,"When SIL was administered for 10 min, the Cmax and bioavailability were 3.46 ± 1.65 µg/mL and 23.2 ± 11.1%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),[μg] / [ml],3.46,227801,DB00203,Sildenafil
,33012742,bioavailability,"When SIL was administered for 10 min, the Cmax and bioavailability were 3.46 ± 1.65 µg/mL and 23.2 ± 11.1%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),%,23.2,227802,DB00203,Sildenafil
,33012742,Cmax,"When SIL was administered for 60 min, the Cmax and bioavailability were 0.990 ± 0.352 µg/mL and 9.91 ± 3.79%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),[μg] / [ml],0.990,227803,DB00203,Sildenafil
,33012742,bioavailability,"When SIL was administered for 60 min, the Cmax and bioavailability were 0.990 ± 0.352 µg/mL and 9.91 ± 3.79%, respectively.",The Pharmacokinetics of Sildenafil May Be Affected by Intestinal Absorption Rate in Children Admitted to the Intensive Care Unit. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33012742/),%,9.91,227804,DB00203,Sildenafil
,24746063,bioavailability,"These limitations include poor solubility and extensive first-pass metabolism, resulting in low (40%) bioavailability and short elimination half-life (4 h).",Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746063/),%,40,238012,DB00203,Sildenafil
,24746063,elimination half-life,"These limitations include poor solubility and extensive first-pass metabolism, resulting in low (40%) bioavailability and short elimination half-life (4 h).",Sildenafil citrate as oral solid lipid nanoparticles: a novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24746063/),h,4,238013,DB00203,Sildenafil
,29467656,bioavailability,"In vivo, compared to both FCT and ODT, ODF showed a faster increase of serum Sild levels (serum levels at 15 min from dosing, respectively: 2.24 ± 1.4 ng/ml FCT, 0.5 ± 0.3 ng/ml ODT, and 13.5 ± 9.1 ng/ml ODF; P < 0.01 and P < 0.05 vs. ODF) together with a higher drug bioavailability within 60 min from dosing (relative AUC60min vs. FCT, respectively: 100.0 ± 44.9% FCT, 183.8 ± 75.4% ODT, and 304.2 ± 156.0% ODF).",Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29467656/),%,100.0,243047,DB00203,Sildenafil
,29467656,bioavailability,"In vivo, compared to both FCT and ODT, ODF showed a faster increase of serum Sild levels (serum levels at 15 min from dosing, respectively: 2.24 ± 1.4 ng/ml FCT, 0.5 ± 0.3 ng/ml ODT, and 13.5 ± 9.1 ng/ml ODF; P < 0.01 and P < 0.05 vs. ODF) together with a higher drug bioavailability within 60 min from dosing (relative AUC60min vs. FCT, respectively: 100.0 ± 44.9% FCT, 183.8 ± 75.4% ODT, and 304.2 ± 156.0% ODF).",Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29467656/),%,183.8,243048,DB00203,Sildenafil
,29467656,bioavailability,"In vivo, compared to both FCT and ODT, ODF showed a faster increase of serum Sild levels (serum levels at 15 min from dosing, respectively: 2.24 ± 1.4 ng/ml FCT, 0.5 ± 0.3 ng/ml ODT, and 13.5 ± 9.1 ng/ml ODF; P < 0.01 and P < 0.05 vs. ODF) together with a higher drug bioavailability within 60 min from dosing (relative AUC60min vs. FCT, respectively: 100.0 ± 44.9% FCT, 183.8 ± 75.4% ODT, and 304.2 ± 156.0% ODF).",Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29467656/),%,304.2,243049,DB00203,Sildenafil
,29467656,relative AUC60min,"In vivo, compared to both FCT and ODT, ODF showed a faster increase of serum Sild levels (serum levels at 15 min from dosing, respectively: 2.24 ± 1.4 ng/ml FCT, 0.5 ± 0.3 ng/ml ODT, and 13.5 ± 9.1 ng/ml ODF; P < 0.01 and P < 0.05 vs. ODF) together with a higher drug bioavailability within 60 min from dosing (relative AUC60min vs. FCT, respectively: 100.0 ± 44.9% FCT, 183.8 ± 75.4% ODT, and 304.2 ± 156.0% ODF).",Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29467656/),%,100.0,243050,DB00203,Sildenafil
,29467656,relative AUC60min,"In vivo, compared to both FCT and ODT, ODF showed a faster increase of serum Sild levels (serum levels at 15 min from dosing, respectively: 2.24 ± 1.4 ng/ml FCT, 0.5 ± 0.3 ng/ml ODT, and 13.5 ± 9.1 ng/ml ODF; P < 0.01 and P < 0.05 vs. ODF) together with a higher drug bioavailability within 60 min from dosing (relative AUC60min vs. FCT, respectively: 100.0 ± 44.9% FCT, 183.8 ± 75.4% ODT, and 304.2 ± 156.0% ODF).",Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29467656/),%,183.8,243051,DB00203,Sildenafil
,29467656,relative AUC60min,"In vivo, compared to both FCT and ODT, ODF showed a faster increase of serum Sild levels (serum levels at 15 min from dosing, respectively: 2.24 ± 1.4 ng/ml FCT, 0.5 ± 0.3 ng/ml ODT, and 13.5 ± 9.1 ng/ml ODF; P < 0.01 and P < 0.05 vs. ODF) together with a higher drug bioavailability within 60 min from dosing (relative AUC60min vs. FCT, respectively: 100.0 ± 44.9% FCT, 183.8 ± 75.4% ODT, and 304.2 ± 156.0% ODF).",Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29467656/),%,304.2,243052,DB00203,Sildenafil
,18800037,terminal half-life,"Volume of distribution of sildenafil in neonates was fourfold higher than in adults, resulting in a longer terminal half-life in neonates (48-56 h) compared to adults.",Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800037/),h,48-56,243442,DB00203,Sildenafil
,11206038,Cmax,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[ng] / [ml],1067.7,244434,DB00203,Sildenafil
,11206038,Cmax,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[ng] / [ml],1517.0,244435,DB00203,Sildenafil
,11206038,AUC,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[h·ng] / [ml],4082.9,244436,DB00203,Sildenafil
,11206038,AUC,"In a single elderly male patient, grapefruit juice increased the Cmax of sildenafil by 42% (1067.7 ng/mL to 1517.0 ng/mL) although AUC was not significantly altered (4082.9 ng x h/mL to 4171.9 ng x h/mL) by grapefruit juice.",Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11206038/),[h·ng] / [ml],4171.9,244437,DB00203,Sildenafil
,16730145,F,"After oral administration (30 mg/kg), approximately 0.626% was not absorbed and F was 14.6%.",Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730145/),%,14.6,247501,DB00203,Sildenafil
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB00203,Sildenafil
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB00203,Sildenafil
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB00203,Sildenafil
,15497717,absolute oral bioavailability,The absolute oral bioavailability is about 15%.,[Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497717/),%,15,250835,DB00203,Sildenafil
,15497717,tmax,Vardenafil is rapidly absorbed with a median tmax of 0.7 h and a terminal half-life (t1/2) of more than 4 h.,[Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497717/),h,0.7,250836,DB00203,Sildenafil
more,15497717,terminal half-life (t1/2),Vardenafil is rapidly absorbed with a median tmax of 0.7 h and a terminal half-life (t1/2) of more than 4 h.,[Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497717/),h,4,250837,DB00203,Sildenafil
,33210997,tmax,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,0.9,260169,DB00203,Sildenafil
,33210997,tmax,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,1,260170,DB00203,Sildenafil
,33210997,T1/2,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,2.4,260171,DB00203,Sildenafil
,33210997,T1/2,"The tmax of sildenafil and N-desmethyl sildenafil was ~ 0.9 hours and 1 hour, and the T1/2 was 2.4 hours and 3.7 hours, respectively.",A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),h,3.7,260172,DB00203,Sildenafil
,33210997,relative bioavailability,The relative bioavailability of sildenafil and N-desmethyl sildenafil was 99.28 ± 3.30% and 99.20 ± 3.39%.,A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),%,99.28,260173,DB00203,Sildenafil
,33210997,relative bioavailability,The relative bioavailability of sildenafil and N-desmethyl sildenafil was 99.28 ± 3.30% and 99.20 ± 3.39%.,A UPLC-MS/MS method for simultaneous quantification of sildenafil and N-desmethyl sildenafil applied in pharmacokinetic and bioequivalence studies in a Chinese population. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33210997/),%,99.20,260174,DB00203,Sildenafil
,14522022,flow rate,"A Capcell Pak C18 UG120 column (150 mm x 4.6 mm I.D., 5 microm) was used as a stationary phase and the mobile phase consisted of 30% acetonitrile and 70% 20mM potassium phosphate buffer (pH 4.5) at a flow rate of 1.0 ml/min.","Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522022/),[ml] / [min],1.0,260966,DB00203,Sildenafil
greater,14522022,recovery,The recovery of DA from human plasma and urine was greater than 70%.,"Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522022/),%,70,260967,DB00203,Sildenafil
,21547677,T(max),"Furthermore, the plasma concentration at 0.25 h in sildenafil lactate was similar to the C(max) value at T(max) (0.5 h) in sildenafil citrate.",Comparison of the solubility and pharmacokinetics of sildenafil salts. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21547677/),h,0.5,261292,DB00203,Sildenafil
,30940497,dose recovery percent,"The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm.",Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940497/),%,68-8 5,265754,DB00203,Sildenafil
,30940497,mass median aerodynamic diameter,"The aerodynamic properties included fine particle fraction ranging between 24 and 30%, dose recovery percent of 68-8 5%, and average mass median aerodynamic diameter of 4.6-4.8 μm.",Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940497/),μm,4.6-4.8,265755,DB00203,Sildenafil
,15963102,C(max),Sildenafil C(max) fell from 759 ng ml(-1) on visit 1 to 333 ng ml(-1) on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).,Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963102/),[ng] / [ml],759,269282,DB00203,Sildenafil
,15963102,C(max),Sildenafil C(max) fell from 759 ng ml(-1) on visit 1 to 333 ng ml(-1) on visit 3 (P < 0.01) and there was a significant decrease in the plasma half-life of sildenafil on the higher bosentan dose (P < 0.05).,Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15963102/),[ng] / [ml],333,269283,DB00203,Sildenafil
,20006565,absolute recovery,The mean absolute recovery for all tested molecules was always found to be close to 100%.,HPLC determination of novel dithiolethione containing drugs and its application for in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006565/),%,100,270692,DB00203,Sildenafil
,23960848,flow rate,Chromatographic separation was achieved on C18 column using methanol:water (85:15 v/v) as mobile phase at a flow rate of 1 ml/min and UV detection at 230 nm.,Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960848/),[ml] / [min],1,273668,DB00203,Sildenafil
,23960848,retention time,The retention time of SIL was found to be 4.0 min having a separation time less than 5 min.,Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960848/),min,4.0,273669,DB00203,Sildenafil
less,23960848,separation time,The retention time of SIL was found to be 4.0 min having a separation time less than 5 min.,Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960848/),min,5,273670,DB00203,Sildenafil
